共 121 条
[21]
Daud A(2018)Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice Future Oncol 357 409-S1288
[22]
Hua C(2017)Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade Science 4 351-1805
[23]
Boussemart L(2018)Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer JAMA Oncol 4 374-74
[24]
Mateus C(2018)Association of immune-related adverse events with nivolumab efficacy in non–small-cell lung cancer JAMA Oncol 5 e1231292-2111
[25]
Al Mushref M(2016)Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer OncoImmunology 7 404-1226
[26]
Guido PA(2018)Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience Transl Lung Cancer Res 12 S1287-A105
[27]
Collichio FA(2017)P3.02c–026 Is nivolumab safe and effective in elderly and PS2 patients with non-small cell lung cancer (NSCLC)? Results of CheckMate 153: Topic: IT J Thorac Oncol 12 1798-1104
[28]
Moore DT(2017)Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a prospective cohort study J Thorac Oncol 115 71-8114
[29]
Clemmons DR(2018)Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab Lung Cancer 71 2100-1928
[30]
Rizvi NA(2019)Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study Arthritis Rheumatol 5 1226-4439